English

Publications

Cabrera O, Berman D, Kenyon N, Ricordi C, Berggren PO, Caicedo A. 2006. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. PNAS. 103: 2334-2339. (Article)

Campbell J, Drucker D. 2015. Islet α cells and glucagon—critical regulators of energy homeostasis. Nature Reviews Endocrinology(PDF)

Greenhill C. 2015. Diabetes: New treatment approach for T1DM. Nat Rev Endocrinol 11: 255-255. (PDF)

Gu W, Lloyd DJ, Chinookswong N, Komorowski R, Sivits G, Jr., Graham M, Winters KA, Yan H, Boros LG, Lindberg RA et al. 2011. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice. J Pharmacol Exp Ther 338: 70-81. (Article)

Gu W, Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q, Wu X, Rulifson IC, Sivits G, Jr., Graham M et al. 2010. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. Am J Physiol Endocrinol Metab 299: E624-632. (Article)

Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V et al. 2009. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 331: 871-881. (Article)

Lau YY, Ma P, Gibiansky L, Komorowski R, Wang J, Wang G, Yan H, Veniant MM, Kakkar T. 2009. Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice. AAPS J 11: 700-709. (Article)

Lee Y, Berglund ED, Wang MY, Fu X, Yu X, Charron MJ, Burgess SC, Unger RH. 2012. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A 109: 14972-14976. (Article)

Lee Y, Berglund ED, Yu X, Wang MY, Evans MR, Scherer PE, Holland WL, Charron MJ, Roth MG, Unger RH. 2014. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. Proc Natl Acad Sci U S A 111: 13217-13222. (Article)

Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. 2011. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60: 391-397. (Article)

Lefèbvre PJ, Paquot N, Scheen AJ. 2015. Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes, Obesity and Metabolism. 1-6. (PDF)

Unger RH, Cherrington AD. 2012. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122: 4-12. (Article)

Unger RH, Orci L. 1975. Physiology and Pathophysiology of Glucagon. Physiologocal Reviews: 56 779-820. (Article)

Unger RH, Orci L. 1975. The essential role of glucagon in the pathogensis of diabetes mellitus. The Lancet: 14-16. (PDF)

Wang M-Y, Yan H, Shi Z, Evans MR, Yu X, Lee Y, Chen S, Williams A, Philippe J, Roth MG et al. 2015. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proceedings of the National Academy of Sciences 112: 2503-2508. (PDF)

Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, Winters KA, Komorowski R, Zhang C, Patel JJ et al. 2009. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 329: 102-111. (Article)